glp-1 agonist and dpp-4 inhibitor Glucagon-like peptide-1 DPP-4 inhibitors and GLP-1RAs: cardiovascular
Description
Innovative Chemistry
Diabetes Care 48 , 905913 (2025)
GLP-1based therapies share several common adverse effects and carry some rare but important risks
Although there is no current evidence that gut neuropeptides or GLP-1 are implicated in the pathogenesis of IIH, these studies do highlight the therapeutic potential for GLP-1 receptor agonist in the management of IIH
Cureus 15, e38630
